help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lanzi, R.
Right arrow Articles by Pontiroli, A. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lanzi, R.
Right arrow Articles by Pontiroli, A. E.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*GLYCERIN
The Journal of Clinical Endocrinology & Metabolism Vol. 82, No. 7 2239-2243
Copyright © 1997 by The Endocrine Society


Clinical Studies

Evidence for an Inhibitory Effect of Physiological Levels of Insulin on the Growth Hormone (GH) Response to GH-Releasing Hormone in Healthy Subjects

R. Lanzi, M. F. Manzoni, A. C. Andreotti, M. E. Malighetti, E. Bianchi, L. Piceni Sereni, A. Caumo, L. Luzi and A. E. Pontiroli

Istituto Scientifico San Raffaele, Cattedra di Medicina Interna (R.L., M.F.M., A.C.A., M.E.M., E.B., L.P.S., L.L., A.E.P.); Unità di Bioingegneria (A.C.), Università degli Studi di Milano, 20132 Milan, Italy

Address all correspondence and requests for reprints to: Roberto Lanzi, M.D., Istituto Scientifico San Raffaele, Via Olgettina 60, 20132 Milano, Italy.

It has been previously reported that in healthy subjects, the acute reduction of free fatty acids (FFA) levels by acipimox enhances the GH response to GHRH. In the present study, the GH response to GHRH was evaluated during acute blockade of lipolysis obtained either by acipimox or by insulin at different infusion rates. Six healthy subjects (four men and two women, 25.8 ± 1.9 yrs old, mean ± SE) underwent three GHRH tests (50 µg iv, at 1300 h) during: 1) iv 0.9% NaCl infusion (1200–1500 h) after oral acipimox administration (250 mg) at 0700 h and at 1100 h; 2) 0.1 mU·kg-1·min-1 euglycemic insulin clamp (1200–1500 h) after oral acipimox administration (250 mg at 0700 h and at 1100 h); 3) 0.4 mU·kg-1·min-1 euglycemic insulin clamp (1200–1500 h) after oral placebo administration (at 0700 and 1100 h).

Serum insulin (immunoreactive insulin) levels were significantly different in the three tests (12 ± 2, 100 ± 10, 194 ± 19 pmol/L, P < 0.05), plasma FFA were low and similar (0.04 ± 0.003, 0.02 ± 0.005, 0.02 ± 0.003, not significant), and the GH response to GHRH was progressively lower (4871 ± 1286, 2414 ± 626, 1076 ± 207 µg/L·120 min), although only test 3 was significantly different from test 1 (P < 0.05). Pooling the three tests together, a significant negative regression was observed between mean serum immunoreactive insulin levels and the GH response to GHRH (r = -0.629, P < 0.01).

Our results indicate that in healthy subjects, acipimox and hyperinsulinemia produce a similar decrease in FFA levels and that at similar low FFA, the GH response to GHRH is lower during insulin infusion than after acipimox. These data suggest that insulin exerts a negative effect on GH release. Because the insulin levels able to reduce the GH response to GHRH are commonly observed during the day, for instance during the postprandial period, we conclude that the insulin negative effect on GH release may have physiological relevance.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
D. Glintborg, R. K. Stoving, C. Hagen, A. P. Hermann, J. Frystyk, J. D. Veldhuis, A. Flyvbjerg, and M. Andersen
Pioglitazone Treatment Increases Spontaneous Growth Hormone (GH) Secretion and Stimulated GH Levels in Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5605 - 5612.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
S. V Haijma, P S. van Dam, W. R de Vries, I. Maitimu-Smeele, C. Dieguez, F. F Casanueva, and H. P F Koppeschaar
The GHRH/GHRP-6 test for the diagnosis of GH deficiency in elderly or severely obese men
Eur. J. Endocrinol., April 1, 2005; 152(4): 575 - 580.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
T. Ostergard, K. B. Degn, M.-A. Gall, R. D. Carr, J. D. Veldhuis, M. K. Thomsen, R. A. Rizza, and O. Schmitz
The Insulin Secretagogues Glibenclamide and Repaglinide Do Not Influence Growth Hormone Secretion in Humans but Stimulate Glucagon Secretion during Profound Insulin Deficiency
J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 297 - 302.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
P. Villa, L. Soranna, A. Mancini, L. De Marinis, D. Valle, S. Mancuso, and A. Lanzone
Effect of feeding on growth hormone response to growth hormone-releasing hormone in polycystic ovarian syndrome: relation with body weight and hyperinsulinism
Hum. Reprod., March 1, 2001; 16(3): 430 - 434.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
C. A. Jaffe, B. W. Huffman, and R. Demott-Friberg
Insulin hypoglycemia and growth hormone secretion in sheep: a paradox revisited
Am J Physiol Endocrinol Metab, August 1, 1999; 277(2): E253 - E258.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1997 by The Endocrine Society